Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice

被引：13
作者：
Golshani, Maryam [1 ]
Rafati, Sima [2 ]
Nejati-Moheimani, Mehdi [3 ]
Ghasemian, Melina [1 ]
Bouzari, Saeid [1 ]
机构：
[1] Pasteur Inst Iran, Dept Mol Biol, Tehran, Iran
[2] Pasteur Inst Iran, Dept Immunotherapy & Leishmania Vaccine Res, Tehran, Iran
[3] Pasteur Inst Iran, Bacterial Vaccine & Antigen Prod Branch, Karaj, Iran
来源：
VETERINARY MICROBIOLOGY | 2016年 / 197卷
基金：
美国国家科学基金会;
关键词：
Brucella melitensis; Brucella abortus; Omp2b; Recombinant protein; DNA vaccine; Prime-boost strategy; Cross protection; OUTER-MEMBRANE PROTEINS; IMPROVED IMMUNOGENICITY; VACCINATION; MELITENSIS; ADJUVANTS; OMP31; IDENTIFICATION; ABORTUS;
D O I：
10.1016/j.vetmic.2016.10.027
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
In the present study, immunogenicity and protective efficacy of the Brucella outer membrane protein 2b (Omp2b) was evaluated in BALB/c mice using Protein/Protein, DNA/DNA and DNA/Protein vaccine strategies. Immunization of mice with three vaccine regimens elicited a strong specific IgG response (higher IgG2a titers over IgG1 titers) and provided Th1-oriented immune response. Vaccination of BALB/c mice with the DNA/Pro regimen induced higher levels of IFN-gamma/IL-2 and conferred more protection levels against B. melitenisis and B. abortus challenge than did the protein or DNA alone. In conclusion, Omp2b is able to stimulate specific immune responses and to confer cross protection against B. melitensis and B. abortus infection. Therefore, it could be introduced as a new potential candidate for the development of a subunit vaccine against Brucella infection. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码：47 / 52
页数：6
相关论文
共 30 条
[1]  
[Anonymous], 2006, WHO LIB CATALOGUE PU
[2]   Adjuvants designed for veterinary and human vaccines [J].
Aucouturier, J ;
Dupuis, L ;
Ganne, V .
VACCINE, 2001, 19 (17-19) :2666-2672
[3]   Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination [J].
Carson, DA ;
Raz, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1621-1622
[4]   Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection [J].
Cassataro, J ;
Estein, SM ;
Pasquevich, KA ;
Velikovsky, CA ;
de la Barrera, S ;
Bowden, R ;
Fossati, CA ;
Giambartolomei, GH .
INFECTION AND IMMUNITY, 2005, 73 (12) :8079-8088
[5]   Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting [J].
Cassataro, Juliana ;
Velikovsky, Carlos A. ;
Bruno, Laura ;
Estein, Silvia M. ;
de la Barrera, Silvia ;
Bowden, Raul ;
Fossati, Carlos A. ;
Giambartolomei, Guillermo H. .
CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (07) :869-874
[6]  
Christopher Supriya, 2010, J Lab Physicians, V2, P55, DOI 10.4103/0974-2727.72149
[7]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[8]   Major outer membrane proteins of Brucella spp.:: past, present and future [J].
Cloeckaert, A ;
Vizcaíno, N ;
Paquet, JY ;
Bowden, RA ;
Elzer, PH .
VETERINARY MICROBIOLOGY, 2002, 90 (1-4) :229-247
[9]   Brucellosis - new aspects of an old disease [J].
Cutler, SJ ;
Whatmore, AM ;
Commander, NJ .
JOURNAL OF APPLIED MICROBIOLOGY, 2005, 98 (06) :1270-1281
[10]   A History of the Development of Brucella Vaccines [J].
Daniel Avila-Calderon, Eric ;
Lopez-Merino, Ahide ;
Sriranganathan, Nammalwar ;
Boyle, StephenM. ;
Contreras-Rodriguez, Araceli .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
123